Seattle Children’s opens first pediatric CAR T-Cell trial targeting CD22 and CD19 proteins

Seattle Children’s opens first pediatric CAR T-Cell trial targeting CD22 and CD19 proteins

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Seattle Children’s has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the U.S. for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously attack two targets on cancer cells. With this more robust defense, researchers hope the new experimental therapy, first being investigated in the phase 1 Pediatric Leukemia Adoptive Therapy (PLAT-05) trial, will ultimately be able to cut the rate of relapse following CAR T-cell therapy by almost half.

“This is an exciting time where we’re at the forefront of advancing the CAR T-cell immunotherapy field by pioneering strategies to improve long-term outcomes for children and young adults,” said Dr. Rebecca Gardner, an oncologist at Seattle Children’s and lead investigator for the PLAT-05 trial. “In launching a bilateral attack on the cancer cells, we hope this trial will help us develop a T-cell therapy that leads to long-term remission for many more of our patients.”

Gardner and the research team, led by Dr. Mike Jensen at the Ben Towne Center for Childhood …

https://www.newsrx.com/Butter/#!Search:a=14742200

(2017-11-30), Seattle Children’s opens first pediatric CAR T-Cell trial targeting CD22 and CD19 proteins, Gene Therapy Weekly, 50, ISSN: 1532-4583, BUTTER® ID: 014742200